Teacher Retirement System of Texas Decreases Stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Teacher Retirement System of Texas decreased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 3.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 637,877 shares of the company's stock after selling 24,920 shares during the period. Teacher Retirement System of Texas owned approximately 0.06% of Teva Pharmaceutical Industries worth $9,804,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Thrivent Financial for Lutherans raised its holdings in Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after buying an additional 699 shares during the last quarter. Bfsg LLC raised its holdings in Teva Pharmaceutical Industries by 7.8% in the first quarter. Bfsg LLC now owns 10,960 shares of the company's stock worth $168,000 after buying an additional 790 shares during the last quarter. Townsquare Capital LLC raised its holdings in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock worth $885,000 after buying an additional 812 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in Teva Pharmaceutical Industries by 27.7% in the fourth quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock worth $96,000 after buying an additional 949 shares during the last quarter. Finally, Blair William & Co. IL raised its holdings in Teva Pharmaceutical Industries by 9.4% in the fourth quarter. Blair William & Co. IL now owns 11,232 shares of the company's stock worth $248,000 after buying an additional 963 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Buying and Selling

In related news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president owned 9,989 shares in the company, valued at approximately $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.55% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on TEVA. Truist Financial initiated coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price for the company. The Goldman Sachs Group initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. UBS Group decreased their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Finally, Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE:TEVA traded down $0.17 during midday trading on Monday, reaching $16.84. The company's stock had a trading volume of 9,689,108 shares, compared to its average volume of 10,278,630. The firm has a market capitalization of $19.31 billion, a PE ratio of 6.97, a P/E/G ratio of 0.87 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The stock has a fifty day moving average of $17.03 and a 200 day moving average of $17.28. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The firm's revenue was up 1.9% on a year-over-year basis. During the same quarter last year, the business earned $0.48 earnings per share. On average, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.